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Incidence of and risk factors for tuberculosis among
people with HIV on antiretroviral therapy in the
United Kingdom
Clare L. van Halsemaa,b, Hajra Okhaic, Teresa Hillc,
Caroline A. Sabinc,d, for the UK Collaborative HIV
Cohort (UK CHIC) Study
Objective: The United Kingdom has a low tuberculosis incidence and earlier combi-
nation antiretroviral therapy (cART) is expected to have reduced incidence among
people with HIV. Epidemiological patterns and risk factors for active tuberculosis were
analysed over a 20-year period among people accessing HIV care at sites participating
in the UK CHIC observational study.
Design: Cohort analysis.
Methods: Data were included for individuals over 15 years old attending for HIV care
between 1996 and 2017 inclusive, with at least 3months follow-up recorded. Incidence
rates of new tuberculosis events were calculated and stratified by ethnicity (white/Black/
other) as a proxy for tuberculosis exposure. Poisson regression models were used to
determine the associations of calendar year, ethnicity and other potential risk factors
after cART initiation.
Results: Fifty-eight thousand seven hundred and seventy-six participants (26.3%
women; 54.5% white, 32.0% Black, 13.5% other/unknown ethnicity; median
(interquartile range) age 34 (29–42) years) were followed for 546 617 person-years.
Seven hundred and four were treated for active tuberculosis [rate 1.3; 95% confi-
dence interval (CI) 1.2–1.4/1000 person-years). Tuberculosis incidence decreased
from 1.3 (1.2–1.5) to 0.6 (0.4–0.9)/1000 person-years from pre-2004 to 2011–2017.
The decline among people of Black ethnicity was less steep than among those of
white/other ethnicities, with incidence remaining high among Black participants in
the latest period [2.1 (1.4–3.1)/1000 person-years]. Two hundred and eighty-three
participants [191 (67%) Black African] had tuberculosis with viral load less than
50 copies/ml.
Conclusion: Despite the known protective effect of cART against tuberculosis, a
continuing disproportionately high incidence is seen among Black African people.
Results support further interventions to prevent tuberculosis in this group.
Copyright  2020 The Author(s). Published by Wolters Kluwer Health, Inc.
AIDS 2020, 34:1813–1821
Keywords: antiretroviral therapy, CD4þ lymphocyte count, ethnic groups, HIV,
tuberculosis
aDepartment of Infectious Diseases and TropicalMedicine, NorthManchester General Hospital, Manchester, bLiverpool School of
Tropical Medicine, Liverpool, cInstitute for Global Health, and dNational Institute for Health Research Health Protection Research
Unit in Blood-Borne and Sexually Transmitted Infections, University College London, London, UK.
Correspondence to Clare L. van Halsema, Department of Infectious Diseases and Tropical Medicine, North Manchester General
Hospital, Delaunays Road, Manchester M8 5RB, UK.
E-mail: clarevh@doctors.org.uk
Received: 30 March 2020; revised: 19 May 2020; accepted: 26 May 2020.
DOI:10.1097/QAD.0000000000002599
ISSN 0269-9370 Copyright Q 2020 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the
Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited. 1813
Introduction
Combination antiretroviral therapy (cART) is strongly
protective against active tuberculosis in people with HIV
across a range of settings [1–3]. The United Kingdom
(UK) has a low incidence of tuberculosis and there is
widespread access to cART, with the UNAIDS 90–90–
90 target for HIV care being met for the first time in 2017
[4]. However, tuberculosis still occurs among individuals
receiving cARTand incidence has been shown to remain
higher than that among people without HIV [5,6].
A previous analysis of the UK Collaborative HIV Cohort
(UK CHIC) study, including data from 1996 to 2005,
showed high incidence of tuberculosis among people
with HIV of Black African ethnicity, despite the
widespread availability of cART and improved CD4þ
cell counts [7]. The risk of tuberculosis was the highest in
those with low CD4þ cell counts and in those of Black
African ethnicity. Since that time, tuberculosis incidence
in the UK has decreased further [8]; people with HIVare
living longer [9,10] and guidelines on the timing of cART
have changed, with immediate rather than CD4þ-guided
start now recommended [11].
The UK CHIC cohort study provides an opportunity to
examine the incidence of tuberculosis among people
engaged in HIV care in the UK across a longer time
period and to identify risk factors for the development of
tuberculosis. We aimed to examine the incidence of
tuberculosis and to identify risk factors for incident
tuberculosis, particularly among those on cART.
Methods
Study participants
The UK CHIC study was initiated in 2001 and collates
routine data on people with HIV, aged at least 16 years,
who have attended one of 25 clinical centres providing
HIV care in the UK at any time from 1996 onwards.
Since 2004, the number of participating centres has
increased from six to 25, with 10 in London, 14 in other
parts of England and one in Edinburgh, Scotland.
Participating centres are in large, urban areas. The study
methods are described fully elsewhere [12]. In brief,
centres collect data on demographic information, cART
history, laboratory results, and AIDS diagnoses (including
any tuberculosis events, classified as either pulmonary,
extra-pulmonary or other/unknown), which are submit-
ted on an annual basis to the co-ordinating centre. The
analyses presented here include data collected up to 31
December 2017. Participants were eligible for analysis if
they entered UK CHIC between 1996 and 2017, had a
follow-up period of at least 3 months and at least 1 CD4þ
T-cell count measurement after entry.
Statistical analysis
Continuous variables were expressed as the median and
interquartile range (IQR), and categorical variables as
counts and percentages. Tuberculosis incidence was
calculated based on the first tuberculosis episode recorded
after entry to UK CHIC, regardless of any previous
episodes that had been reported to occur prior to study
entry. If tuberculosis was detected within 3 months of
entry, we excluded follow-up time for that individual
during the period of tuberculosis treatment (assumed to
be 6 months after the tuberculosis episode date) to
exclude tuberculosis disease that was most likely present at
study entry and thus follow-up time for such individuals
started 6 months after tuberculosis diagnosis.
To investigate factors independently associated with the
occurrence of a tuberculosis event after starting cART, we
used Poisson regression models. As this analysis was
limited to those who initiated cART, follow-up started at
cART initiation and ended at the earliest of date of
tuberculosis episode, date of loss to follow-up or 31
December 2017. The date of the tuberculosis episode is
defined as the date when the clinic reported tuberculosis
as an AIDS event.
We examined associations with age, ethnicity (white;
Black; other/unknown), a combined variable of sex and
mode of HIV acquisition (sex between men; male
heterosexuals; female heterosexuals; male other mode;
female other mode), and clinical data after cART
initiation (including CD4þ T-cell count, hepatitis B/C
status and HIV viral load). Factors that were significantly
associated with the risk of tuberculosis in univariable
models were selected for inclusion in the multivariable
model. In a subsequent analysis, we then further explored
the effect of ethnicity on tuberculosis risk, using a more
detailed breakdown of ethnicity: Black Caribbean, Black
African, Black other, south Asian/other Asian, mixed/
other and unknown.
Ethical approval
UK CHIC was approved by a Multicentre Research
Ethics Committee (MREC/00/7/47) and by local
ethics committees.
Results
Description of cohort and tuberculosis events
Overall, 73 843 UK CHIC participants attended HIV
clinics across the UK between 1996 and 2017. Of these,
933 individuals had at least one tuberculosis event after
entry to UK CHIC, of which 57.9% were pulmonary
tuberculosis. We excluded 15 067 study participants (229
tuberculosis events) because of insufficient follow-up
time (n¼ 1490), missing CD4þ T-cell data (n¼ 2060) or
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both (n¼ 11 517), leaving 58 776 in the analyses with 704
tuberculosis events.
Study participants are described in Table 1. The median
age at entry was 34 (interquartile range [IQR]: 29–42)
years, but this increased from 33 years for those entering
the study before 2004 to 37 years for those entering after
2011. The majority of study participants were of white
ethnicity (54.5%), male (73.7%) and had a primary mode
of HIV acquisition of sex between men (MSM, 52.3%).
Participants were followed for a total of 546 617 person-
years (PYRS) with a median follow-up time of 8.2 years
[IQR: 3.6–13.8].
Median CD4þ T-cell count at study entry was 385 (IQR:
220–570) cells/ml, although this increased from 307
(IQR: 153–480) pre-2004 to 494 (IQR: 316–677) in the
most recent time-period (post-2011). Similarly, the
median HIV viral load at entry decreased over time
from 3.7 (IQR: 2.2–4.7) log10 copies/ml pre-2004 to 2.0
(IQR: 1.7–3.7) log10 copies/ml post-2011.
In total, 704 individuals had at least one tuberculosis event
over a median follow-up time of 3.4 (IQR: 1.4–6.6) years
(incidence: 1.3/1000 PYRS, 95% confidence interval
1.2–1.4). Just over half of tuberculosis events were
pulmonary events (56.5%), followed by extra pulmonary
(38.8%) and other/unknown (4.7%) events. Most (58.1%,
409/704) tuberculosis events occurred after cART
initiation with 69.2% (283/409) of these post-cART
events occurring among individuals who had a suppressed
(50 copies/ml) HIV viral load at the time of their
tuberculosis episode. The median CD4þ T-cell count at
the time of diagnosis was 260 (IQR 130–430) cells/ml.
Though our analyses are restricted to the first tuberculosis
event, 74 (10.5%) of these individuals had a subsequent
tuberculosis episode recorded; individual characteristics
at the time of these recurrent events were similar to those
of the first tuberculosis event.
Tuberculosis incidence over time
The incidence of tuberculosis decreased over time
(Fig. 1(i)), with an incidence in the most recent period
(post-2011) of 0.6/1000 PYRS (95% CI 0.4–0.9)
compared with 1.4/1000 PYRS (95% CI 1.2–1.5) in
the pre-2004 period. The incidence of tuberculosis was
the highest in those of Black ethnicity [2.8/1000 PYRS
(95% CI 2.6–3.1)] compared with those of white (0.6/
1000 PYRS [95% CI 0.5–0.7]) or other/unknown (1.0/
1000 PYRS [95% CI 0.8–1.3]) ethnic groups. The
decline over time was apparent in all ethnic groups,
although was less marked in those of Black ethnicity than
in the other groups. Patterns of decline were broadly
similar regardless of whether individuals were untreated
[295 events over 213 604 PYRS, Fig. 1(ii)] or had started
cART [409 events over 331 893 PYRS, Fig. 1(iii)].
Risk factors for tuberculosis among individuals
taking combined antiretroviral therapy
In a univariable analysis of the 44 628 participants who
started cART (Table 2), of 409 tuberculosis episodes after
cART initiation, 21 (5.1%) occurred within 3 months; 29
(7.1%) 3–6 months after cART initiation; 51 (12.5%) 6–
12 months after and 308 (75%) after 12 months on ART.
Older participants were less likely to experience a
tuberculosis event, as were those with a lower HIV viral
load or higher CD4þ T-cell count over follow-up, those
who initiated cART in more recent years and those who
had been on cART for a longer period of time. MSM
were the group with the lowest risk of a tuberculosis event
when compared with all other sex/mode of HIV
acquisition groups. Participants from the Black and
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Table 1. Characteristics of individuals included in analyses of tuberculosis incidence.
Year of study entry
Total
(n¼58595)
<2004
(n¼22515)
2004–2007
(n¼11797)
2008–2011
(n¼10991)
>2011
(n¼13473)
Age at UK CHIC entry (median, IQR)
Years 34 (29–42) 33 (28–39) 35 (29–41) 36 (29–43) 37 (29–46)
Sex (n, %)
Male 43197 (73.7) 17068 (76.3) 7857 (66.6) 7706 (70.1) 10 566 (78.4)
Female 15425 (26.3) 5295 (23.7) 3939 (33.4) 3285 (29.9) 2906 (21.2)
Ethnicity (n, %)
White 32036 (54.5) 13577 (60.3) 5655 (47.9) 5506 (50.1) 7298 (54.2)
Black 18781 (32.0) 6225 (27.6) 5002 (42.4) 4059 (36.9) 3495 (25.9)
Other/unknown 7959 (13.5) 2713 (12.1) 1140 (9.7) 1426 (13.0) 2680 (19.9)
Mode of HIV acquisition (n, %)
MSM 30745 (52.3) 12614 (56.0) 5230 (44.3) 5045 (45.9) 7856 (58.3)
Sex between men and women 21582 (36.7) 7265 (32.3) 5616 (47.6) 4701 (42.8) 4000 (29.7)
Other 6449 (11.0) 2636 (11.7) 951 (8.1) 1245 (11.3) 1617 (12.0)
CD4þ T-cell count at UK CHIC entry (median, IQR)
(cells/ml) 385 (220–570) 307 (153–480) 355 (215–522) 403 (251–574) 494 (316–677)
Log10 HIV VL at UK CHIC entry (median, IQR)
(copies/ml) 2.8 (1.7–4.3) 3.7 (2.2–4.7) 3.2 (1.7–4.4) 2.8 (1.7–4.3) 2.0 (1.7–3.7)
IQR, inter-quartile range; MSM, men who have sex with men (MSM); VL, viral load.
other/unknown ethnic groups had a higher risk of
tuberculosis compared with the white population. Most
associations remained similar in the multivariable model
(Table 3), with the exception of the association with age,
which was attenuated and became nonsignificant
after adjustment.
After stratifying the multivariable model by year of cART
initiation (Table 3), the association with Black ethnic
group appeared to strengthen over time, with an adjusted
risk ratio in the post-2011 period (relative to the pre-2004
period) of 5.05 compared with values of 2.47–3.32 in the
earlier periods. A test of interaction between Black
1816 AIDS 2020, Vol 34 No 12
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Fig. 1. Tuberculosis incidence rate stratified by year of entry to UK CHIC and ethnicity in (i) all UK CHIC participants
(tuberculosis eventsU704), (ii) individuals not receiving cART (tuberculosis eventsU295), and (iii) individuals receiving cART
(tuberculosis eventsU 409). cART, combination antiretroviral treatment.
ethnicity and calendar period confirmed that the rate in
the Black ethnic group was significantly higher than
would be expected based on the overall patterns for
calendar period and ethnicity (P¼ 0.02 for interaction
term). There is also a strong association between
heterosexual route of HIV acquisition and persistently
high tuberculosis incidence, with adjusted rate ratio for
active tuberculosis of 2.3 (1.57–2.26) for male hetero-
sexuals and 2.40 (1.67–3.46) for female heterosexuals
compared with those reporting sex between men as the
route of HIVacquisition. This is likely to be explained by
residual confounding, with a large proportion of
heterosexual adults (15 432/21 582 [71.5%]) being of
Black African ethnicity. Of 18 781 people of Black
African ethnicity, 15 432 (82.1%) report heterosexual
acquisition.
As the white ethnic group had very low risk of
tuberculosis, we performed a further analysis without
this group to focus more on differences between minority
ethnic groups (Fig. 2). In this analysis, including 331
tuberculosis episodes, occurring at median CD4þ cell
count 299 cells/ml (IQR 170–489), ethnicity remained
strongly associated with the risk of a tuberculosis event,
with those of Black African origin having a higher risk of
tuberculosis compared with those of Black Caribbean
origin in both univariable and multivariable models
[crude RR: 2.45 (1.40–4.27); adjusted RR: 2.10 (1.19–
3.70)]. There was no evidence of a higher risk of
tuberculosis among the other ethnic groups when
compared with the Black Caribbean group.
Discussion
In this UK cohort of people with HIV, tuberculosis still
occurs among those receiving cART with incidence in
the most recent time period (2011–2017) of 0.6/1000
PYRS compared with incidence in the general UK
population at the time of around 0.13/1000 [8].
Incidence of tuberculosis among people with HIV has
reduced with time; this is likely to be multifactorial,
including association with overall reduction in
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Table 2. Analysis of risk factors for tuberculosis after starting combination antiretroviral treatment.
Variable Events/person-years RR (95% CI) P value
Ethnicity White 78/182659 1 0.01
Black 300/117075 6.00 (4.68–7.70)
Other/unknown 31/32159 2.26 (1.49–3.42)
Age /10 years 0.69 (0.63–0.77) 0.01
HIV viral load (time-updated) Log10 copies/ml 1.80 (1.68–1.93) 0.01
CD4þ cell count (time-updated) /100 cells/ml 0.70 (0.66–0.73) 0.01
Years since cART initiation /additional year 0.87 (0.85–0.90) 0.01
Year cART initiated /later year 0.96 (0.95–0.98) 0.01
Sex/mode of acquisition Sex between men 68/172020 1 0.01
Male heterosexual 111/49921 5.62 (4.16–7.61)
Female heterosexual 199/86446 5.82 (4.42–7.67)
Male other mode 17/15716 2.74 (1.61–4.66)
Female other mode 14/7276 4.87 (2.74–8.65)
Results reported are from separate univariable Poisson regression models. 95% CI, 95% confidence interval; cART, combination antiretroviral
treatment; RR, rate ratio.
Table 3. Analysis of risk factors for tuberculosis after starting combination antiretroviral treatment, overall and stratified by year of combination
antiretroviral treatment initiation.
All years <2004 2004–2007 2008–2011 >2011
Variable aRR (95% CI) P value aRR (95% CI) P value aRR (95% CI) P value aRR (95% CI) P value aRR (95% CI) P value
Ethnicity White 1 0.01 1 0.01 1 0.02 1 0.03 1 0.01
Black 3.13 (2.23–4.38) 3.32 (2.05–5.37) 2.47 (1.29–4.72) 2.84 (1.24–6.50) 5.05 (1.31–19.51)
Other/unknown 1.85 (1.20–2.85) 1.82 (0.97–3.45) 1.94 (0.87–4.33) 2.04 (0.72–5.80) 1.55 (0.25–9.48)
Age /10 years 0.96 (0.86–1.08) 0.52 1.00 (0.84–1.19) 0.98 0.86 (0.70–1.06) 0.16 0.86 (0.66–1.12) 0.25 1.21 (0.84–1.75) 0.32
HIV viral load
(time-updated)
Log copies/ml 1.43 (1.32–1.55) 0.01 1.50 (1.34–1.67) 0.01 1.33 (1.14–1.57) 0.01 1.49 (1.23–1.79) 0.01 1.18 (0.84–1.66) 0.37
CD4þ cell count
(time-updated)
/100 cells/ml 0.85 (0.80–0.89) 0.01 0.86 (0.80–0.92) 0.01 0.92 (0.84–1.00) 0.05 0.78 (0.68–0.89) 0.01 0.69 (0.55–0.85) 0.01
Years since cART
initiation
/additional year 0.95 (0.92–0.99) 0.01 0.90 (0.87–0.94) 0.01 0.87 (0.82–0.93) 0.01 0.76 (0.67–0.87) 0.01 0.61 (0.42–0.91) 0.01
Year cART initiated /later year 0.93 (0.91–0.95) 0.01
Sex/exposure Sex between men 1 0.01 1 0.27 1 0.01 1 0.01 1 0.08
Male heterosexual 2.30 (1.57–3.36) 1.52 (0.89–2.59) 2.56 (1.17–5.63) 4.38 (1.61–11.90) 6.30 (1.18–33.82)
Female heterosexual 2.40 (1.67–3.46) 1.70 (1.03–2.81) 3.05 (1.46–6.39) 3.86 (1.46–10.25) 3.85 (0.70–21.21)
Male other mode 1.81 (1.05–3.11) 1.14 (0.48–2.71) 3.48 (1.31–9.27) 2.10 (0.53–8.26) 3.86 (0.51–29.15)
Female other mode 2.44 (1.34–4.47) 1.97 (0.86–4.53) 5.63 (2.1–15.12) – –
Results are from a multivariable Poisson regression model. 95% CI, 95% confidence interval; aRR, adjusted rate ratio for incident tuberculosis;
cART, combination antiretroviral treatment.
tuberculosis incidence in the UK [8] and with the higher
CD4þ cell count at entry to the study and earlier start of
cART [11]. Public Health England data show that in
2017, 75% of those diagnosed with HIV with a CD4þ cell
count greater than 350 cells/ml start cARTwithin 91 days
of diagnosis, compared with 30% in 2013 [4].
Ethnicity is a key risk factor for incident tuberculosis,
with the Black African group continuing to have high
incidence even after cART start and with this group not
seeing the same fall in incidence evident in other ethnic
groups. As expected, a lack of virological suppression and
low CD4þ cell count are associated with incident
tuberculosis but, despite this, most tuberculosis episodes
occurred among individuals who were virologically
suppressed on cART and most after 12 months on
cART. The lack of data on birth or long-term residence in
countries of higher tuberculosis incidence means that
ethnicity used as a proxy for this may misclassify some
and, therefore, the calculated measures of effect may be
smaller than the true effect. It is known that, in countries
of low tuberculosis incidence, a disproportionate number
of incident tuberculosis cases occur among those born
elsewhere, with slower decrease in incidence among
individuals born outside those countries. This has been
described in the UK as well as elsewhere in Europe and in
the United States [8,13–15]. There are published
strategies for targeted prevention, focused on identifying
and treating latent tuberculosis infection among people
moving from countries of high tuberculosis incidence to
those of low incidence and people with HIV are a key
group for whom this intervention should be provided
[16,17].
In Table 3, an association is shown between heterosexual
mode of HIVacquisition and tuberculosis risk, even after
controlling for age, sex, ethnicity, CD4þ cell count and
viral load. The epidemiology of HIV in the UK is such
that the majority of people reporting sex between men as
a route of acquisition are UK-born or of white ethnicity,
or both, and the majority of people reporting heterosex-
ual sex as mode of HIVacquisition are of Black African or
other ethnicity or born in countries of high tuberculosis
incidence. Route of HIV acquisition is not causally
related to risk of active tuberculosis and the observed
association is likely to be attributable to residual,
unmeasured confounding.
Current guidance for diagnosis and treatment of latent
tuberculosis among people with HIV in the UK is
provided by the British HIVAssociation (BHIVA) and the
National Institute for Health and Care Excellence
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Fig. 2. Unadjusted and adjustedR relative risk of tuberculosis after starting combination antiretroviral treatment, ethnicity
subgroup analysis. Adjusted for age, HIV viral load, CD4þ cell count, years since cART initiation and year of cART initiation. 95%
CI, 95% confidence interval; cART, combination antiretroviral treatment; RR, rate ratio.
(NICE) [18,19]. The 2011 BHIVA guidance [20] was in
place during the most recent time period in this study,
2011–2017, and recommended testing for latent
tuberculosis (and treating if present) according to
epidemiological, immunological and cART criteria.
The updated 2018 guideline [18] widens the recommen-
dation to include all those from high and medium
tuberculosis incidence countries and those from low
incidence countries with additional risk factors or low
CD4þ cell count. These recommendations are, however,
poorly implemented [21,22] and missed opportunities for
prevention of active tuberculosis are frequent [23],
meaning that it is unlikely that the reduction in incidence
seen in this analysis is attributable to treatment of
latent tuberculosis.
This analysis builds on the previous UK CHIC paper
[7], which included data up to 2005 and showed an
increased risk of incident tuberculosis in people of Black
African ethnicity compared with others, despite over 2
years of cART and a declining UK tuberculosis
incidence at the time. Our findings are consistent with
other analyses from countries with low tuberculosis
incidence, in which greater tuberculosis risk is found
among Black African, Asian and Hispanic participants
with HIV than among white study participants with
HIV [6,24]. This strongly suggests a greater need for
prevention methods, including earlier HIV diagnosis
and implementation of testing and treatment for latent
tuberculosis infection according to existing guidelines.
Treatment of latent tuberculosis along with cART for
people with HIV is a well evidenced intervention,
showing an effect in addition to cART on tuberculosis
risk, including among individuals with higher CD4þ
cell counts [25–27] albeit largely demonstrated in high
tuberculosis-incidence settings. It is recommended by
national and international guidelines [28] and in
strategies for the elimination of tuberculosis in countries
of low tuberculosis incidence [29].
A strength of this study is the large number of individuals
included and follow-up time, the systematic data
collection and good data on ethnicity and cART, with
updated CD4þ cell counts. Limitations include the
limited detail of clinical data on tuberculosis episodes,
categorizing as pulmonary, extra-pulmonary or other/
unknown, with unknown numbers microbiologically
confirmed; the lack of data on place of birth or long-term
residence and the use of ethnicity as a proxy for exposure
to tuberculosis in a country of higher tuberculosis
incidence. In addition, data are not collected on treatment
of latent tuberculosis infection, although, as detailed
above, coverage of this in the UK is thought to be low.
In conclusion, despite falling tuberculosis incidence in the
UK, including among people with HIV, tuberculosis
incidence remains disproportionately high among Black
African people. This is despite the protective effect of
cART and supports more widespread implementation of
prevention strategies for those at risk.
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